Jähne J, Urmacher C, Albino A, Meyer H J, Pichlmayr R
Klinik für Abdominal- und Transplantationschirurgie, Zentrum Chirurgie, Medizinische Hochschule Hannover.
Chirurg. 1994 Apr;65(4):307-11.
In 58 gastric carcinomas the expression of the Her2/neu gene product p185 was immunohistochemically analyzed. Fresh tumor tissue for molecular studies was available in 25 cases. The results were correlated with various pathohistological and prognostic factors. A 16-32fold Her2/neu amplification was found in 20% of the tumors (n = 5). The oncogene product p185 was detected at the basement membrane in 38% of the tumors (n = 22). Amplification and p185 overexpression occurred in intestinal, but not diffuse type carcinomas (p < 0.001). p185 expression was independent from tumor site and tumor stage, but correlated with pT-stage (p < 0.001). Overall prognosis was influenced by tumor stage and R-classification, but not by p185 expression. Multivariate analysis, however, defined patients with stage IIIA/B and IV and R0-resection who had a poorer survival in case of p185 expression (p < 0.05). Her2/neu amplification and p185 overexpression appear to be characteristic molecular events in intestinal type gastric carcinogenesis and may help in identifying a subgroup of patients at increased risk for shorter survival.
对58例胃癌患者的Her2/neu基因产物p185进行了免疫组织化学分析。25例患者有可用于分子研究的新鲜肿瘤组织。结果与各种病理组织学和预后因素相关。20%的肿瘤（n = 5）中发现Her2/neu基因扩增16 - 32倍。38%的肿瘤（n = 22）在基底膜检测到癌基因产物p185。扩增和p185过表达见于肠型而非弥漫型癌（p < 0.001）。p185表达与肿瘤部位和肿瘤分期无关，但与pT分期相关（p < 0.001）。总体预后受肿瘤分期和R分级影响，但不受p185表达影响。然而，多变量分析确定，IIIA/B期和IV期且行R0切除的患者，若有p185表达则生存较差（p < 0.05）。Her2/neu基因扩增和p185过表达似乎是肠型胃癌发生过程中的特征性分子事件，可能有助于识别生存期较短风险增加的患者亚组。
